Epidemiology of viral hepatitis in the Maghreb

##plugins.themes.academic_pro.article.sidebar##

Published Nov 13, 2018
Download
pdf
Vol. 96 No. 10 (2018): Issue Oct 2018

##plugins.themes.academic_pro.article.main##

M. Lahlali
H. Abid
A. Lamine
N. Lahmidani
M. El Yousfi
D. Benajah
M. El Abkari
A Ibrahimi
N. Aqodad

Abstract

Introduction: Viral hepatitis represents a serious public health problem in the world especially in the Maghreb where the prevalence of the 5 viruses A, B, C, D, and E remains high and varies from one Maghreb country to another, there is few published studies on these infections in our Maghreb countries.
Method of study: Our work is a review of the literature about prevalence, the most common mode of transmission, and the most exposed population for these viruses in the Maghreb countries through published studies between 2011 and 2017.
Result: It has been found that the Maghreb countries are endemic for the five viruses with variable prevalence from one country to another, with sometimes heterogeneous data in the same country. For hepatitis B, Mauritania is the Maghreb country most affected by this infection unlike the rest of the Maghreb countries which are moderately endemic for this virus, the lowest prevalence of VHB was noted in Morocco, the genotype the most common is the D for the majority of Maghreb countries, and the precore mutant profile is also the most common. For hepatitis C the prevalence of infection does not vary much from one Maghreb country to another, but it remains slightly higher in Mauritania. The population most exposed to the virus C in the five countries is hemodialysis patients. The most common genotype in all Maghreb countries is genotype 1 except for Libya, where genotype 4 remains the most common probably related to its borders with Egypt. For hepatitis D, Mauritania is the only Maghreb country with a high endemicity for the virus. Tunisia has the lowest prevalence for hepatitis A and E compared to the rest of the Maghreb countries, all of which are endemic for these two viruses with fecal-oral transmission.
Conclusion: The management of these viral hepatitis is costly for the health economy and to reduce their prevalence, prevention measures must be followed like vaccination and improving hygiene conditions.

Keywords:

Hepatitis - Hepatitis, Viral, Human - Hepatitis A- Hepatitis B - Hepatitis C - Hepatitis D - Hepatitis E - Epidemiology - Public Health - Seroepidemiologic Studies - Africa Northern

##plugins.themes.academic_pro.article.details##

References

  1. Botelho-Souza et al: Hepatitis delta: virological and clinical aspects/Virology Journal (2017) 14:177 doi: 10.1186/s12985-017-0845-y
  2. S.Ezzikouri et al: Hepatitis B virus in the Maghreb Region: from epidemiology to prospective research/Viral Hepatitis Laboratory, Pasteur Institute of Morocco, Casablanca, Morocco, Liver International ISSN 1478-3223 (2013)
  3. McLean AA. Hepatitis B vaccine: a review of the clinical data to date. J Am Dent Assoc.1985; 110:624-8.
  4. Hou J et al. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2005; 2:50-7.
  5. Read JS et al. Prevention of mother-to-child transmission of viral infections. Curr Probl Pediatr Adolesc Health Care 2008; 38:274-97.
  6. André F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000;18:20-2.
  7. Barkat A et al. Calendrier national de vaccination évolution et perspectives. Available from: http://www.santemaghreb.com
  8. A. Sbai et al. Hepatitis B prevalence and risk factors in Morocco/ Pathologie Biologie 60 (2012) e65-e69
  9. Mohammed Sbiti et al. Séroprévalence de l'Ag HBs chez la femme enceinte dans le centre du Maroc/Pan African Medical Journal. 2016;24:187 doi:10.11604/pamj.2016.24.187.9849
  10. Sekkat M. Prévalence de l'Ag HBs chez les femmes enceintes: résultats préliminaires d'une étude prospective menée au CHU Hassan II Fès Maroc, à propos de 156 cas. 2010. http://scolarite.fmpusmba. ac.ma/cdim /médiathèque/mémoires/mémoires /13- 10.pdf. Accessed 05 Mai 2016.PubMed
  11. Zineb Lioussfi et al. Viral Hepatitis C and B among Dialysis Patients at the Rabat University Hospital: Prevalence and Risk Factors / Saudi J Kidney Dis Transpl 2014; 25(3):672-679
  12. K. Djeriri et al. Hepatitis B in Moroccan health care workers, Occupational Medicine 2008; 58:419-424 Published online 18 June 2008 doi: 10.1093/ occmed /kqn071
  13. B. Adouani Hepatitis B in Moroccan blood donors: a decade trend of the HBs Ag prevalence in a resources limited country/Transfusion Medicine 2013 British Blood Transfusion Society doi: 10.1111/tme.12054
  14. J.Uwingabiye et al. : Séroprévalence des marqueurs viraux sur les dons du sang au Centre de Transfusion sanguine, Hôpital Militaire d'Instruction Mohammed V de Rabat/Pan African Medical Journal. 2016; 25:185 doi:10.11604/pamj.2016.25.185.6266
  15. O.Bahri : Epidémiologie de l'hépatite virale B en Tunisie, institut Pasteur, Laboratoire de virologie clinique, Tunis, Tunisie/Médecine et maladies infectieuses 38(2008) S192-S192
  16. Coursaget P et al. Hepatitis C core antibody detection in acute hepatitis and cirrhosis patients from Tunisia. Pathol Biol (Paris) 1992; 40: 646-8.
  17. Triki H et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg 1997; 91: 11-4.
  18. Houissa R et al. Épidémiologie de l'hépatite B en Tunisie. Arch Inst Pasteur Tunis 1988; 65 : 53-8. 10.
  19. Triki Épidémiologie des virus des hépatites B, C et Delta dans la population générale et les cirrhoses hépatiques en Tunisie. Arch Inst Pasteur Tunis 1994,71:4036.
  20. Hannachi N et al. Viral infection risk in polytransfused adults: seroprevalence of seven viruses in central Tunisia (French). Bull Soc Pathol Exot 2011; 104: 220-5. 38.
  21. Langar H et al. Blood-transmitted viral infections among hemophiliacs in Tunisia (French).Transfus Clin Biol 2005; 12: 301-5.
  22. El Goulli N et al. Hepatitis B virus infection in Tunisia. IARC Sci Publ 1984 ; 63 : 199-211.
  23. Houissa R et al. Épidémiologie de l'hépatite B en Tunisie. Arch Inst Pasteur Tunis 1988; 65 : 53-8.
  24. Coursaget P et al. Familial clustering of hepatitis B virus infections and prevention of perinatal transmission by immunization with a reduced number of doses in an area of intermediate endemicity (Tunisia).Vaccine 1994; 12: 275-8.
  25. Maaref et al. Prévalence de l'hépatite G et des hépatites virales B et C dans la population VIH (+) de l'hôpital La Rabta, Tunis, Tunisie, F. / Pathologie Biologie 59 (2011) 213-216
  26. Hannachi N et al. Hepatitis B virus infection in Tunisian pregnant women: risk factors and viral DNA levels in HBe antigen negative women (French).Pathol Biol (Paris) 2009; 57: e43-7.
  27. Triki H et al.High circulation of hepatitis B virus (HBV) precore mutants in Tunisia, North Africa. Epidemiol Infect 2000; 125: 167-74.
  28. L. Safer, et al. Epidémiologie des hépatites virales en Tunisie, /Rev Epidemiol Sante Publique, 2006, 54 : 377-383
  29. Gorgi Y et al. Prevalence of viral hepatitis B markers in the region of Tataouine (southern Tunisia) (French). Arch Inst Pasteur Tunis 1989; 66: 251-61.
  30. Marano C, Freedman DO. Global health surveillance and travelers' health. Curr Opin Infect Dis. 2009;22:423-9
  31. Couturier E et al.Cluster of cases of hepatitis A with a travel history to Egypt, September-November 2008, France. Euro Surveill. 2009
  32. Bensalem A. Widespread geographical disparities in chronic hepatitis B virus infection in Algeria/ Arch Virol DOI 10.1007/s00705-017-3284-6
  33. Khelifa F, Thibault V. Characteristics of hepatitis B viral strains in chronic carrier patients from North-East Algeria. Pathol Biol 2009; 57:107-13.
  34. Instruction N°15 du 01 Septembre 2016 relatif au renforcement du programme de prévention et de lutte contre les hépatites B et C (Direction générale de la prévention et de la promotion de la santé, Algérie)
  35. Elzouki A et al. Prevalence of hepatitis B, C and HIV infection in Libya: a population- based nationwide sero- epidemiological study.Liver International 2006; 26:Supp 1, 20
  36. Elzouki A Hepatitis B infection in Libya: The magnitude of the problem. The Libyan Journal of Infectious Diseases, 2008, 2: 20-25.
  37. Alashek et al. Hepatitis B and C infection in hemodialysis patients in Libya: prevalence, incidence and risk factors, BMC Infectious Diseases 2012, 12:265
  38. Ziglam H et al.Prevalence of antibodies to human immunodeficiency virus, hepatitis B, and hepatitis C in prisoners in Libya/ Libyan J Med 2012, 7: 1971 http://dx.doi.org/10.3402/ljm.v7i0.19713
  39. Abdel, A.-N. Elzouki et al Hepatitis B and C status among healthcare workers in the five main hospitals in eastern Libya / http://dx.doi.org/10.1016/j.jiph.2014.07.006 ART 82
  40. Saint Martins J et al. Prevalence of hepatitis B markers in Mauritania / Transactions of the royal society of tropical medicine and hygiene (1 987)‘ 31, 525-526
  41. Lo BB.Prevalence of serum markers of hepatitis B and C virus in blood donors of Nouakchott, Mauritania/Bull Soc Pathol Exot. 1999 May; 92(2):83-4
  42. RuiWZ et al Hepatitis B virus infection in the school milieu of Kiffa and Selibaby, Mauritania, /Bull Soc Pathol Exot. 1998;91(3):247-8.
  43. Desenclos JC. L'infection par le virus de l'hépatite C dans le monde : importance en santé publique, modes de transmission et perspectives. Virologie 2003; 7: 177-91.
  44. S. Benjelloun, B et al. “Anti-HCV seroprevalence and risk factors of hepatitis C virus infection in Moroccan population groups,” Research in Virology, vol. 147, no. 4, pp. 247-255, 1996.
  45. W. Baha et al., “Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco,” BMC Public Health, vol. 13, article 50, 2013.
  46. B.O. M.Abdelaali et al. “Hepatitis C viral prevalence and seroconversion in Moroccan hemodialysis units: eight year follow up,” Journal of Medical Diagnostic Methods, vol. 2, p. 141, 2013.
  47. I. Belbacha, I. et al. “Seroprevalence of hepatitis B and C among barbers and their clients in the Rabat region of Morocco,” Eastern Mediterranean Health Journal, vol. 17, no. 12, pp. 911-919, 2011.
  48. R.-D. Trimbitas et al. “The ‘hidden' epidemic: a snapshot of Moroccan intravenous drug users,” Virology Journal, vol. 11, no. 1, article 43, 2014.
  49. I. Brahim et al. “Morocco underwent adrift of circulating hepatitis C virus subtypes in recent decades,” Archives of Virology, vol. 157, no. 3, pp. 515-520, 2012.
  50. H. Triki et al. “Seroepidemiology of hepatitis B, C and delta viruses in Tunisia, «Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 91, no. 1,pp. 11-14, 1997.
  51. S.Mejri et al. “Contrasting patterns of hepatitis C virus infection in two regions from Tunisia,” Journal of Medical Virology, vol. 76, no. 2, pp. 185-193, 2005
  52. N. Kaabia et al., “Association of hepatitis C virus infection and diabetes in central Tunisia,” World Journal of Gastroenterology, vol. 15, no. 22,pp. 2778-2781, 2009
  53. R. Ben Jemia and E. Gouider, “Seroprevalency of transfusion transmitted infections in first-time volunteer and replacement donors in Tunisia,” Transfusion Clinique et Biologique, vol. 21, no. 6, pp.303-308, 2014.
  54. R.Debbeche et al. “Epidémiologie de l'hépatite C en Tunisie. Tunis Med 2013 ; 91(2) : 86-91.
  55. F. Sassi et al. “Hepatitis C virus antibodies in dialysis patients in Tunisia: a single center study,” Saudi Journal of Kidney Diseases and Transplantation, vol. 11, pp. 218-222, 2000
  56. A. Djebbi et al. “Genotypes of hepatitis C virus circulating in Tunisia,” Epidemiology and Infection, vol. 130, no. 3, pp. 501-505, 2003
  57. F. H. Kchouk et al., “Phylogenetic analysis of isolated HCV strains from tunisian hemodialysis patients,” Viral Immunology, vol. 26, no. 1, pp. 40-48, 2013
  58. A. Bensalem, K. et al., “Eastern region represents a worrying cluster of active hepatitis C in Algeria in 2012,”Journal of Medical Virology, vol. 88, no. 8, pp. 1394-1403, 2016
  59. National Travel Health Network Centre (NATHNAC), Country Information, Algeria, Tunisia, Morocco, 2009
  60. Z. Ayed, D et al. “Prevalence of serum markers of hepatitis B and C in blood donors and pregnant women in Algeria,” Bulletin de la Société de Pathologie Exotique, vol. 88, no. 5, pp. 225-228, 1995
  61. S. Rouabhia et al. “Hepatitis C virus genotypes in north eastern Algeria: a retrospective study,” World Journal of Hepatology, vol. 5, no. 7, pp. 393-397, 2013
  62. M. A. Daw and A. El-Bouzedi, “Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey,” BMC Infectious Diseases, vol. 14, article 17, 2014
  63. W. A. Alashek et al. “Hepatitis B and C infection in hemodialysis patients in Libya: prevalence, incidence and risk factors/” BMC Infectious Diseases,vol.12, article 265, 2012
  64. M. A. Daw et al. “Geographic distribution of HCV genotypes in Libya and analysis of risk factors involved in their transmission,” BMC Research Notes, vol. 8, article 367, 2015
  65. H. A. Elasifer et al. “Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients,” Virology Journal, vol. 7, article 317, 2010
  66. Mohamed A. Daw et al. Hepatitis C Virus in North Africa: An Emerging Threat, The Scientific World Journal, Volume 2016, Article ID 7370524
  67. Botelho-Souza L et al : Hepatitis delta: virological and clinical Aspects/ Virology Journal (2017) 14:177 DOI 10.1186/s12985-017-0845-y
  68. Wael Mansour et al. : Virological and epidemiological features of hepatitis delta infection among blood donors in Nouakchott, Mauritania/ W. Mansour et al./ Journal of Clinical Virology 55 (2012) 12- 16
  69. Lunel-Fabiani F et al.Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: A cross sectional study/ The British Infection Association. http://dx.doi.org/10.1016/j.jinf.2013.06.008
  70. Wael Mansour et al. Prevalence, Risk Factors, and Molecular Epidemiology of Hepatitis B and Hepatitis Delta Virus in Pregnant Women and in Patients in Mauritania/ J. Med. Virol 84:1186-1198 (2012) DOI 10.1002/jmv
  71. Abdel-Naser Elzouki et al : Prevalence and risk factors of hepatitis D virus infection in patients with chronic hepatitis B infection attending the three main tertiary hospitals in Libya/ / Arab Journal of Gastroenterology (2017) https://doi.org/10.1016/j.ajg.2017.11.003
  72. Mallem L : thèse en médecine : indications thérapeutiques aux différents stades évolutifs des porteurs chroniques du virus de l'hépatite B/Faculté de Médecine d'Oran 2015
  73. Khelifa et al: caractéristiques des souches virales responsables d'hépatites B chroniques en Algérie du Nord-Est/Pathologie biologie 57(2009) 107-113
  74. A. Djebbi et al. Marqueurs sérologiques, ARN viral et génotype du virus de l'hépatite delta chez des patients tunisiens antigène HBs positifs / A. Djebbi et al. / Pathologie Biologie 57 (2009) 518-523
  75. Triki H et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans Soc Trop Med Hyg 1997; 91:11-4.
  76. Jenhani F et al. Delta infection in chronic HBs Ag carriers in Tunisia: high prevalence in chronic asymptomatic HBs Ag carriers and in HBs Ag positive cirrhosis. Ann Trop Med Paras 1990; 84:349-53.
  77. Yacoubi L et al.: Molecular epidemiology of Hepatitis B and Delta Virus Strains that Spread in the Mediterranean North East Coast of Tunisia/ Journal of Clinical Virology JCV 3444/ http://dx.doi.org/doi:10.1016/j.jcv.2015.10.002 ART 30
  78. Rioche M et al. Low occurrence of delta agent infections in Morocco/Bull Soc Pathol Exot Filiales. 1987; 80(5):741-4.
  79. Kandoussi N et al. HDV Coinfection Rates in Moroccan Chronic Hepatitis B Patients/ SM J Hepat Res Treat. 2017; 3(1): 1013
  80. N. M. Melhem et al.Hepatitis A virus in the Middle East and North Africa region: a new challenge/Journal of Viral Hepatitis, 2014, 21, 605-615 doi:10.1111/jvh.12282
  81. D. Rezig et al. : Séroprévalences des infections à hépatite A et E en Tunisie/Pathologie Biologie 56 (2008) 148-153
  82. Abir Beji-Hamza et al.Migration pattern of hepatitis A virus genotype IA in North-Central Tunisia/Virology Journal (2015) 12:17 DOI 10.1186/s12985-015-0249-9
  83. Letaief A et al. Age-specific seroprevalence of hepatitis a among school children in central Tunisia. Am J Trop Med Hyg 2005; 73: 40-3.
  84. Sanaa M. Kamal et al. Viral Hepatitis A to E in South Mediterranean Countries/Medit J Hemat Infect Dis 2009, 2(1): e2010001, DOI 10.4084/MJHID.2010.001.
  85. Pröll S, Nothdurft HD. The risk of contracting hepatitis A or hepatitis B run by visitors to the Mediterranean and Eastern Europe MMW Fortschr Med. 2004 13;146:51-4
  86. Arya SC, Agarwal N. Hepatitis A and E: Update on prevention and epidemiology. Vaccine. 2009 Dec 29
  87. Fitz Simons D et al. Update on prevention and epidemiology. Vaccine. 2010 8; 28:583-8
  88. Smahi MC et al. Seroprevalence and risk factors of hepatitis A among children in Tlemcen (north-west Algeria). Arch Pediatr 2009; 16(6): 844-846.
  89. W. Guenifi et al. Changement de la prévalence de l'hépatite A et facteurs associés à Sétif, Algérie/Rev Epidemiol Sante Publique (2017) http://dx.doi.org/10.1016/j.respe.2017.05.009
  90. UN Statistics Division. National accounts main aggregates database, December2015 data [online resource]. New York: United Nations; 2015.
  91. United Nations Development Program. Human development report 2014.New York: UNDP; 2014.
  92. Gebreel AO, Christie AB. Viral hepatitis in children: a study in Libya. Ann Trop Pediatr. 1983; 3:9-11.
  93. M. Bouskraoui1 et al. : Prévalence des anticorps de l'hépatite A chez l'enfant dans la région de Marrakech/Archives de Pédiatrie 2009; 16 : S132-S136
  94. Organisation mondiale de la santé. Hépatite E information pharmaceutique. 1993; 7(3):1.
  95. Pillot J. Le virus de l'hépatite E. Cour de microbiologie tropicale.1996;3:5-6.
  96. Castera L, Pawlotsky JM. Hépatite virale E : épidémiologie et prévention. Gastroenterol Clin Biol 2001,25: 521-37.
  97. María A et al. Hepatitis E: An emerging disease. Infection, Genetics and Evolution. 2014; 22:40-59
  98. Hannachi N et al. Séroprévalence et facteurs de risque de l'hépatite virale E chez la femme enceinte dans le centre tunisien. Pathol Biol. 2009; 59(5) :115-118.
  99. Aamoum N et al. Séroprévalence de l'hépatite E à Casablanca .Médecine et maladies infectieuses. 2004;34:491-492.
  100. Lahlou L et al. Séroprévalence des anticorps anti-hépatite virale E (HVE) à l'hôpital militaire d'instruction Mohamed V de Rabat, Maroc. Revue d'Épidémiologie et de Santé Publique. Septembre 2014; 62 Suppl 5:S232.
  101. Neffati H et al.Seroprevalence of hepatitis E virus infection in rural and urban populations, Tunisia/3 February 2012 Clin Microbiol Infect 2012; 18: E119-E121 10.1111/j.1469-0691.2012.03793.x
  102. Rezig D et al. Seroprevalences of hepatitis A and E infections in Tunisia. Pathol Biol (Paris) 2008; 56: 148-153
  103. Blackard JT et al. Genotypic characterization of symptomatic hepatitis E virus (HEV) infections in Egypt. J Clin Virol 2009; 46: 140-144.
  104. Benjelloun S et al. Seroepidemiological study of an acute hepatitis E outbreak in Morocco. Res Virol 1997; 148: 279-287.
  105. Ben Halima M et al. Epidemiology of hepatitis E in Tunisia. Tunis Med 1998; 76(5):129-33.
  106. Rezig D et al. Séroprévalence des infections à hépatite A et E en Tunisie. Pathol Biol (Paris) 2008; 56(3):148-53.
  107. Ben-Ayed Y et al. Hepatitis E Virus Seroprevalence Among Hemodialysis and Hemophiliac Patients in Tunisia (North Africa)/ Journal of Medical Virology (2014) /DOI 10.1002/jmv.24082.
  108. Coursaget P et al. Etiology of acute sporadic hepatitis in adults in Senegal and Tunisia. Scand J Infect Dis 1995; 27: 9-11.
  109. Ben Halima M et al. Épidémiologie de l'hépatite E en Tunisie. Tunisie Médicale 1998; 76:129-31.
  110. Baltenneck E et al. : Thèse en Médecine, Hépatite E, l'Université de Lorraine Nancy (2000).
  111. Van Cuyck-Gandré H et al. Characterization of hepatitis E virus (HEV) from Algeria and Chad by partial genome sequence. J Med Virol. 1997; 53:340-7
  112. Ghannoum MA et al.The incidence of water-related diseases in the Brak area, Libya from 1977 to 1979, before and after the installation of water treatment plants. Zentralbl Bakteriol Mikrobiol Hyg B. 1981; 173:501-8
  113. Sayeh Ezzikouri et al.Hepatitis C Virus Infection in the Maghreb Region/Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc (2013) DOI 10.1002/jmv.23643
  114. Stratégie mondiale du secteur de la santé contre l'hépatite virale 2016-2021, vers l'élimination de l'hépatite virale/L'organisation mondiale de la santé (Juin 2016)
  115. Société Marocaine des Maladies de l'Appareil Digestif SMMAD. Impact de l'observance sur l'efficacité du traitement de l'hépatite C virale. Practice: étude observationnelle non interventionnelle. .
  116. Société Marocaine d'Infectiologie Pédiatrique Et de Vaccinologie (SOMIPEV) : Enquête multicentrique de SOMIPEV : séroprévalence de l'hépatite A au Maroc (2017)/http://www.somipev.ma